BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 7 Publications

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	M2HLO2tqdmG\|ZTDhd5NigQ>?			NUHSSpVWcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDJS2YuOVJiKFnDOVAhRSBzM37NLUBidmRidHjlJIRwf26\|dILlZY0hfGG{Z3X0d{BCc3RiKFnDOVAhRSB{Mn7NLUBidmRiTVHQT{ApUUN3MDC9JFE{dk1r	MmHzNVk4PzhyMkS=
IGF-Sal	NHPDPY9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=			MoHpTWM2OD15IH7N	MoTqNVk4PzhyMkS=
CCRF-CEM (ALL)	NHvKZWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFm2UZh,PSEQvF2=	MUfEUXNQ	NXvDO3JKUUN3ME2xMlI{QSEQvF2=	NGXxRnQyQTl7NkK3Ni=>
PC3	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXf+OUDPxE1?	NWPrfmtJTE2VTx?=	MXjJR\|UxRTBwOU[1JO69VQ>?	MoX6NVk6QTZ{N{K=
JD	MlzQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3W2O542KM7:TR?=	NFnTSHRFVVOR	MXnJR\|UxRTBwM{mxJO69VQ>?	MXixPVk6PjJ5Mh?=
DU145	NG[x[WZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVz+OUDPxE1?	NXfZXGQ1TE2VTx?=	M3\KcmlEPTB;MT60OlUh\|ryP	NEPqOWwyQTl7NkK3Ni=>
KAG	Ml\wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVn+OUDPxE1?	M4ey[mROW09?	MV;JR\|UxRTFwNk[1JO69VQ>?	NYS1V\|M{OTl7OU[yO\|I>
K-562 (CML)	NGr1[YlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXf+OUDPxE1?	MWfEUXNQ	NVv3UIU5UUN3ME2yMlMxOiEQvF2=	M1[1T\|E6QTl4Mkey
B6-P210 (Murine ALL)	NFP1dYNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWPlcIpLhjVizszN	MnjiSG1UVw>?	MVjJR\|UxRTFwMkmzJO69VQ>?	MlPaNVk6QTZ{N{K=
LN CAP-FGC	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXG1Uo1IhjVizszN	Ml:wSG1UVw>?	M4PnNWlEPTB;MT60N\|Qh\|ryP	MWWxPVk6PjJ5Mh?=
VW	NV;nN45rT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3LFTJ42KM7:TR?=	NUPSUosxTE2VTx?=	Mn63TWM2OD1yLkCxPUDPxE1?	NVu2clVbOTl7OU[yO\|I>
MV411 (B Myelomonocytic)	NIDEfllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnfYglUh\|ryP	M4Dib2ROW09?	NIjNVZdKSzVyPUCuN\|Mh\|ryP	MlPjNVk6QTZ{N{K=
MDA-PCa-2b	Mmr4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUfWUmFwhjVizszN	M1zGfmROW09?	NGf1WYxKSzVyPUCuNFk5KM7:TR?=	NXPEPJc1OTl7OU[yO\|I>
LG	NVezd2g5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnnmglUh\|ryP	MV3EUXNQ	M2nWXGlEPTB;MD6wN\|gh\|ryP	MX6xPVk6PjJ5Mh?=
RS411 (B cell precursor-ALL)	NFPwdoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnW2glUh\|ryP	M2PjbWROW09?	MWHJR\|UxRTBwMUCyJO69VQ>?	M4PhS\|E6QTl4Mkey
22-r-1	MmjiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXzPWHNzhjVizszN	NF3DUXBFVVOR	MVjJR\|UxRTBwMUe1JO69VQ>?	NGDz[oQyQTl7NkK3Ni=>
5838	NWSxWIVrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFXHXHJ,PSEQvF2=	M3nYNWROW09?	NXvhWHNsUUN3ME2wMlA{PCEQvF2=	Ml;oNVk6QTZ{N{K=
P388 (Murine)	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mnq3glUh\|ryP	M4DpbWROW09?	Mny3TWM2OD12LkK3JO69VQ>?	MkKyNVk6QTZ{N{K=
A2780/S	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmXxglUh\|ryP	NWDXNHVGTE2VTx?=	NHziS2lKSzVyPUCuNVIzKM7:TR?=	NW\Qc3dzOTl7OU[yO\|I>
RDES	NHq5ZZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnXuglUh\|ryP	MmDBSG1UVw>?	MmDFTWM2OD1yLkCxNkDPxE1?	NXS0RVJmOTl7OU[yO\|I>
B6-T315I (Murine B-ALL)	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXjUcpVXhjVizszN	NH3vXZVFVVOR	NX:3O3R4UUN3ME2yMlg{KM7:TR?=	NGLIdY4yQTl7NkK3Ni=>
TOV 112D	NVXIfZdUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlLQglUh\|ryP	Mkn6SG1UVw>?	Mn3XTWM2OD1{LkG0OkDPxE1?	M3uzTlE6QTl4Mkey
TC32	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYOxWoNuhjVizszN	NHPBUG1FVVOR	MlrKTWM2OD1yLkCwPEDPxE1?	NH64SJQyQTl7NkK3Ni=>
HL60 (acute myelocytic)	M3[4fGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVf+OUDPxE1?	MV\EUXNQ	MUXJR\|UxRTBwMUKg{txO	Ml64NVk6QTZ{N{K=
TOV 21G	M3rGW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlWwglUh\|ryP	MlfkSG1UVw>?	M3PUOWlEPTB;ND6yO\|kh\|ryP	NXrJXHBuOTl7OU[yO\|I>
TC71	NYjWW\|lPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWP+OUDPxE1?	NV3lR2JETE2VTx?=	M2\PO2lEPTB;MD6wNVQh\|ryP	NXqzTWVbOTl7OU[yO\|I>
HPN-ALL (T-cell)	M13OS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkTDglUh\|ryP	MmDpSG1UVw>?	NVf2ToEyUUN3ME2wMlUzKM7:TR?=	M4qzcFE6QTl4Mkey
A2780R	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIna[WF,PSEQvF2=	MV7EUXNQ	Mmj6TWM2OD1zLkW2OEDPxE1?	MlThNVk6QTZ{N{K=
Rh1	NWPBfFBTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{\JdZ42KM7:TR?=	MXvEUXNQ	M4jpPWlEPTB;MD6wNlch\|ryP	NVPXT2Q5OTl7OU[yO\|I>
Kasumi-1 (acute myeloid)	M1zzVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXf+OUDPxE1?	M1PYU2ROW09?	MlTSTWM2OD1yLkG2JO69VQ>?	M4WwVlE6QTl4Mkey
sk-ov-3	M{L4dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYrEVXdbhjVizszN	NHrWNVlFVVOR	NH3hSY1KSzVyPUWuNUDPxE1?	M1fZR\|E6QTl4Mkey
ME	M3nMNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MonIglUh\|ryP	NInpdJNFVVOR	Mo\xTWM2OD1yLkCxOUDPxE1?	MknaNVk6QTZ{N{K=
L1210 (Murine lymphocytic)	NHPt[5lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3HtOp42KM7:TR?=	MWXEUXNQ	MlzDTWM2OD1{LkO5JO69VQ>?	NH7VeW4yQTl7NkK3Ni=>
sw-626	M2D3Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mnm3glUh\|ryP	MY\EUXNQ	Mlm1TWM2OD1{LkOwOkDPxE1?	M1LBTFE6QTl4Mkey
CTR	M4HrSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVHMT3pYhjVizszN	M4PSWGROW09?	NFTOeVRKSzVyPUCuNlU{KM7:TR?=	NYXDN3VMOTl7OU[yO\|I>
ML2 (Myelomonocytic)	NHnoeYNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHXycJR,PSEQvF2=	M171R2ROW09?	MUXJR\|UxRTBwMEmg{txO	NFOyWnMyQTl7NkK3Ni=>
ovcar-3	M4nnS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUjiSVJMhjVizszN	NGLVO5JFVVOR	NUmz[JNJUUN3ME21JO69VQ>?	MXuxPVk6PjJ5Mh?=
Rh36	MoPSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYWx[pZqhjVizszN	MmjDSG1UVw>?	MkO4TWM2OD1zLkSzNkDPxE1?	M2LZdVE6QTl4Mkey
MOLM-13 (acute myeloid)	NHTVPJVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVXYSFdWhjVizszN	M3;PdmROW09?	MnT3TWM2OD1yLkSyJO69VQ>?	MX6xPVk6PjJ5Mh?=
ovcar-4	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3yxXZ42KM7:TR?=	NGjjXVNFVVOR	M33aUmlEPTB;MTFOwG0>	NG\mbG8yQTl7NkK3Ni=>
Rh41	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MV3+OUDPxE1?	NUfIS4Q2TE2VTx?=	NGPTU5BKSzVyPUCuNFA2KM7:TR?=	MVqxPVk6PjJ5Mh?=
Mutz 2 (acute myeloid)	MkG1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1j6[542KM7:TR?=	MUnEUXNQ	MVvJR\|UxRTFwMUWg{txO	NV7jRW1xOTl7OU[yO\|I>
ovcar-5	M1fCWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH33S4R,PSEQvF2=	NULSTINHTE2VTx?=	MXnJR\|UxRTBwMEWg{txO	MVexPVk6PjJ5Mh?=
RD1	M4S5N2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWH+OUDPxE1?	Mmf0SG1UVw>?	NWTQe2dOUUN3ME2wMlA3QCEQvF2=	M2j2bVE6QTl4Mkey
OCI-AML 2 (acute myeloid)	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUfUdG9{hjVizszN	M3XMUGROW09?	MXLJR\|UxRTNwM{Og{txO	MlnONVk6QTZ{N{K=
786-O	M1vxcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{jpUZ42KM7:TR?=	MXfEUXNQ	NVzrZ\|F4UUN3ME2xMlY1PyEQvF2=	M4Dyc\|E6QTl4Mkey
A673	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXn+OUDPxE1?	MYTEUXNQ	NXTFXJEyUUN3ME2wMlQxQCEQvF2=	NEnyTIMyQTl7NkK3Ni=>
TALL-1 (T-cell)	NWqz[W1oT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF\RWlR,PSEQvF2=	MnezSG1UVw>?	M3vqW2lEPTB;MT6yPEDPxE1?	NIXVOWsyQTl7NkK3Ni=>
151-B	NIP4OWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXLTR44xhjVizszN	MXHEUXNQ	NHHid2dKSzVyPUKuOlch\|ryP	NIjsTHEyQTl7NkK3Ni=>
PFSK-1	NU\TVYRwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUD+OUDPxE1?	NVXRcVhxTE2VTx?=	MXHJR\|UxRTBwMUOyJO69VQ>?	M3;Z[lE6QTl4Mkey
THP-1	M2Dod2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHmyWFF,PSEQvF2=	NH[5U4dFVVOR	M2TtN2lEPTB;Nj61PEDPxE1?	MmPUNVk6QTZ{N{K=
HEK293	NHr2dm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYX+OUDPxE1?	NIe1TZVFVVOR	MnXtTWM2OD1yLkmxOUDPxE1?	MV2xPVk6PjJ5Mh?=
DAOY	NU\xO25vT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUPNcHRIhjVizszN	MknuSG1UVw>?	NH;xN4ZKSzVyPUGuPVc6KM7:TR?=	NYC1SnlHOTl7OU[yO\|I>
SET2	NXXKRXl3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnjjglUh\|ryP	NUfMTWpvTE2VTx?=	MXjJR\|UxRTBwMkm4JO69VQ>?	NH;DWIUyQTl7NkK3Ni=>
HTB-46	NUX3dFZIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWr+OUDPxE1?	MULEUXNQ	NYrUVplOUUN3ME21MlI2KM7:TR?=	Mk\0NVk6QTZ{N{K=
SK-NAS	NW\CXIFmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVr+OUDPxE1?	MX;EUXNQ	MUDJR\|UxRTBwNEm3JO69VQ>?	M3XaVVE6QTl4Mkey
CTLL2	M3rTZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXT+OUDPxE1?	NYnNVIlOTE2VTx?=	NED0[pVKSzVyPkGuNFAh\|ryP	Mn7iNVk6QTZ{N{K=
HTB-47	NES0d\|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MV3+OUDPxE1?	M4HsV2ROW09?	MWTJR\|UxRTJwMEW2JO69VQ>?	M1nPdVE6QTl4Mkey
LAN-1	NEPHdWtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2DZdp42KM7:TR?=	NH7VdXNFVVOR	M2DufWlEPTB;MD6wOEDPxE1?	M1PlT\|E6QTl4Mkey
ST486	NFXXbIdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml;MglUh\|ryP	MlrHSG1UVw>?	NIiybWVKSzVyPUGuNVkh\|ryP	MmPqNVk6QTZ{N{K=
HS766T	NIPrSWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEf6cJN,PSEQvF2=	NGfFfI1FVVOR	NYHPXml5UUN3ME2yMlAxOSEQvF2=	M2Wy[lE6QTl4Mkey
IMR-32	NGHONllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NF33dVl,PSEQvF2=	NULPWIdLTE2VTx?=	M3yzUmlEPTB;MD6yOlEh\|ryP	NUiydGhKOTl7OU[yO\|I>
Daudi (Burkitt's)	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVfld21XhjVizszN	NV3pTY5mTE2VTx?=	MYTJR\|UxRTJwNkO3JO69VQ>?	MXyxPVk6PjJ5Mh?=
Aspc-1	NUTkVGd4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NX7idYt1hjVizszN	MlfXSG1UVw>?	NXXmbHdzUUN3ME2wMlM4QSEQvF2=	M4DPcVE6QTl4Mkey
SK-NSH	MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV;Rcpo6hjVizszN	NUm3b2dOTE2VTx?=	NX[xWGV6UUN3ME2wMlE{QSEQvF2=	MoDkNVk6QTZ{N{K=
MEC-1 (Chronic B cell)	Mn;1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3;2PZ42KM7:TR?=	MUHEUXNQ	M{nn[2lEPTB;Mj62N\|ch\|ryP	NF:wPXkyQTl7NkK3Ni=>
Capan-2	NVvYdoE2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF\mdnF,PSEQvF2=	M4nHbWROW09?	M4rjTWlEPTB;MT63O\|Qh\|ryP	NEDzdGMyQTl7NkK3Ni=>
SHSY5Y	Ml7LS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX;+OUDPxE1?	NITWTmZFVVOR	NIDJNpdKSzVyPUCuNVA3KM7:TR?=	MUSxPVk6PjJ5Mh?=
U937 (Histioocytic)	MkC5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3nzbp42KM7:TR?=	M{nBR2ROW09?	NWHmNYY4UUN3ME61MlAxKM7:TR?=	M33kblE6QTl4Mkey
Bxpc-1	M2jUbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUP+OUDPxE1?	NH;5dIhFVVOR	MVTJR\|UxRTFwOUK0JO69VQ>?	MkTONVk6QTZ{N{K=
Bxpc-3	NXq3S4oxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkDuglUh\|ryP	MUPEUXNQ	M{PQ[2lEPTB-NT6wNEDPxE1?	MoTDNVk6QTZ{N{K=
HTB-92	Mme5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4jtdp42KM7:TR?=	MlrISG1UVw>?	MkHpTWM2OD1zLkCyJO69VQ>?	MWGxPVk6PjJ5Mh?=
OCI-LY10 (B-cell)	NFXFWXFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2DZWZ42KM7:TR?=	M3:x[2ROW09?	MlPSTWM2OD1yLkS1JO69VQ>?	NHnJSXkyQTl7NkK3Ni=>
PANC-1	M2O5PGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mo\5glUh\|ryP	NIPCWW5FVVOR	MVHJR\|UxRjVwMECg{txO	M{HWeFE6QTl4Mkey
To184.T	Mmj3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIP0Vnp,PSEQvF2=	MXvEUXNQ	M{i4TGlEPTB;MD60Olkh\|ryP	MY[xPVk6PjJ5Mh?=
OCI-LY19 (B-cell)	MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGrtSHR,PSEQvF2=	MXXEUXNQ	MXjJR\|UxRTBwNDFOwG0>	M2nIcFE6QTl4Mkey
PANC-1 BM	NHS4RoVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mm\tglUh\|ryP	M3vtVWROW09?	NIjsO2VKSzVyPkWuNFAh\|ryP	NHy2WGEyQTl7NkK3Ni=>
SA-4	NHnJOmRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIPW[lN,PSEQvF2=	NYnEfldCTE2VTx?=	NFO1S5BKSzVyPUGuN\|AyKM7:TR?=	M1O2S\|E6QTl4Mkey
RPMI 8226	MmGyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEjofo1,PSEQvF2=	NFjuc2ZFVVOR	MXvJR\|UxRTFwMkmzJO69VQ>?	M1\3W\|E6QTl4Mkey
HPAF-II	M4D3Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX;+OUDPxE1?	M4PoSGROW09?	MlrCTWM2OD1yLk[0OEDPxE1?	M1njeVE6QTl4Mkey
SHP-77	NFfpNVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUn+OUDPxE1?	MYnEUXNQ	MXXJR\|UxRTFwOEi4JO69VQ>?	MYmxPVk6PjJ5Mh?=
U266 B1	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWmwO483hjVizszN	MUXEUXNQ	NHrobVlKSzVyPUGuOlY6KM7:TR?=	M2TUSlE6QTl4Mkey
Hs700t	NWnOXXR{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYP+OUDPxE1?	NWnNOlNbTE2VTx?=	MXnJR\|UxRTBwMkOxJO69VQ>?	NYHtZmRGOTl7OU[yO\|I>
NCI-446	M{i1bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHLBN2l,PSEQvF2=	NX7OdlVKTE2VTx?=	NX;ScI5YUUN3ME2xMlE2PCEQvF2=	MoHMNVk6QTZ{N{K=
H929	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEPU[G9,PSEQvF2=	NXjUOpZXTE2VTx?=	M4nkZmlEPTB;MD6wNVQh\|ryP	NYHqOYtWOTl7OU[yO\|I>
PL45	M4TtVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXT+OUDPxE1?	NHPuPIZFVVOR	NXjrPXhnUUN3ME2yMlI2PSEQvF2=	M3\5SFE6QTl4Mkey
NCI-H383	MoTLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYH+OUDPxE1?	NF7yb4ZFVVOR	MVfJR\|UxRjVwMECg{txO	MkiwNVk6QTZ{N{K=
JJN3	MmPRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWH+OUDPxE1?	NX6zS3g{TE2VTx?=	MnPlTWM2OD1{LkSzN{DPxE1?	M{DPeVE6QTl4Mkey
SU.86.86	NF\2NmlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3[2bZ42KM7:TR?=	MnjYSG1UVw>?	NHnscXlKSzVyPUKuOlczKM7:TR?=	MlzhNVk6QTZ{N{K=
H1299	NUXne4c1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEH4Xnl,PSEQvF2=	MkDrSG1UVw>?	MXvJR\|UxRjVwMECg{txO	MVWxPVk6PjJ5Mh?=
MDA-MB-468	MoHSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4HvUZ42KM7:TR?=	NWDmSFU{TE2VTx?=	MXfJR\|UxRTBwNUC0JO69VQ>?	NXHGNW16OTl7OU[yO\|I>
SW1990	NX2zTYJ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYTmXnVzhjVizszN	Moe2SG1UVw>?	NWrRRWdHUUN3ME2wMlgzPiEQvF2=	M3zCSlE6QTl4Mkey
Calu-6	NGTPcIFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXXBXGpUhjVizszN	NHG4fG9FVVOR	NXLTc4R[UUN3ME61MlAxKM7:TR?=	NIO3OpIyQTl7NkK3Ni=>
MDA-MB-231	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWHFc3FWhjVizszN	M3nOdGROW09?	M17T[WlEPTB;MT62OFgh\|ryP	MYmxPVk6PjJ5Mh?=
SW-684	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFHKfJd,PSEQvF2=	M2L1[GROW09?	Ml7TTWM2OD53LkCwJO69VQ>?	NF72dZUyQTl7NkK3Ni=>
H209	NXvIbYRsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXHGcpdHhjVizszN	NHzmXZBFVVOR	NFLhWplKSzVyPUGuNVk{KM7:TR?=	NHv6[3gyQTl7NkK3Ni=>
MDA-MB-231T	M{D6Nmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVmyepEyhjVizszN	Mnf1SG1UVw>?	NUG0VnJ3UUN3ME61MlAxKM7:TR?=	MWCxPVk6PjJ5Mh?=
HT1080/S	Mn25S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NW\2cHF7hjVizszN	MUXEUXNQ	M1f4SGlEPTB;MD61N\|Eh\|ryP	MkDoNVk6QTZ{N{K=
H526 0.044	NEThWHRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3[5bp42KM7:TR?=	Mn3DSG1UVw>?	MnLPTWM2OD1yLkC0OEDPxE1?	NI\ISFkyQTl7NkK3Ni=>
DU4475 2.431	MoHKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mki2glUh\|ryP	MWXEUXNQ	NY\nXlhEUUN3ME2yMlQ{OSEQvF2=	NImxb2YyQTl7NkK3Ni=>
HCT116	NXjhPW1nT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVP+OUDPxE1?	NXzab\|JCTE2VTx?=	M3XuPWlEPTB;MD64OVIh\|ryP	NXP2b2lTOTl7OU[yO\|I>
M109	MnT4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MljlglUh\|ryP	MoOySG1UVw>?	MXTJR\|UxRTFwMEW1JO69VQ>?	M3vabFE6QTl4Mkey
BT549	Mn3PS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmjlglUh\|ryP	NFrBR2hFVVOR	Ml7DTWM2OD1zLk[0OUDPxE1?	NEK1PZEyQTl7NkK3Ni=>
HCT116/VM46	NFXnSJNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmLxglUh\|ryP	MUnEUXNQ	NHX0emVKSzVyPUGuO\|AzKM7:TR?=	MYGxPVk6PjJ5Mh?=
H460	NX3aOYhPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVj+OUDPxE1?	NHe0dYNFVVOR	NXy3cY1[UUN3ME2wMlc6PSEQvF2=	NF25cJMyQTl7NkK3Ni=>
MCF-7	NWWw[HVQT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVm4RoRDhjVizszN	MVPEUXNQ	M2XadWlEPTB;MD6wNVYh\|ryP	MX[xPVk6PjJ5Mh?=
GEO	NEfIOY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4HwfJ42KM7:TR?=	M13mR2ROW09?	NFjXZoRKSzVyPUCuN\|U3KM7:TR?=	M2jPeFE6QTl4Mkey
H441 0.646	MmP4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnXkglUh\|ryP	NV2xdpJ6TE2VTx?=	NUjTS45TUUN3ME2wMlY1PiEQvF2=	NFvDcFIyQTl7NkK3Ni=>
MCF-7-807R	Mn;GS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH74Znp,PSEQvF2=	MlPSSG1UVw>?	MYTJR\|UxRTBwNEmg{txO	MXWxPVk6PjJ5Mh?=
Colo205	NEPkcVJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmnaglUh\|ryP	NVLuT2UzTE2VTx?=	MmPLTWM2OD1yLkGwOEDPxE1?	MUixPVk6PjJ5Mh?=
H292	NFnuPZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmDQglUh\|ryP	NHvidI9FVVOR	M3HxXGlEPTB;MD63PFgh\|ryP	NUnSdphMOTl7OU[yO\|I>
BT474 (S)	NEGyPW1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkjLglUh\|ryP	MYHEUXNQ	NH;3XlhKSzVyPUKuOFA{KM7:TR?=	Ml7FNVk6QTZ{N{K=
HT-29	NYCzVnMyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkXrglUh\|ryP	MnG1SG1UVw>?	NHzzRXdKSzVyPUKuNVA{KM7:TR?=	MYOxPVk6PjJ5Mh?=
A549	NFjUfFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M13IfZ42KM7:TR?=	NWP3dJhMTE2VTx?=	M2TERWlEPTB;MD62O\|Uh\|ryP	M3rvV\|E6QTl4Mkey
BT474-M1	MknQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIm5b2J,PSEQvF2=	NXe2N5ZqTE2VTx?=	MoixTWM2OD1{LkO2OUDPxE1?	MY[xPVk6PjJ5Mh?=
SW480	MlvpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWLMbW42hjVizszN	NHLvb2FFVVOR	NVnnVos2UUN3ME61MlAxKM7:TR?=	NUOzOpA3OTl7OU[yO\|I>
L2987	M1;tWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1mwUp42KM7:TR?=	MXjEUXNQ	NVjES4hxUUN3ME2wMlQ1OiEQvF2=	MmrUNVk6QTZ{N{K=
AU565	NVW3VmdbT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmDxglUh\|ryP	MUPEUXNQ	NWXaUoFuUUN3ME20Mlk4KM7:TR?=	MkDQNVk6QTZ{N{K=
SW403	M2jhd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXf+OUDPxE1?	NHrHeY5FVVOR	MVPJR\|UxRTBwMkKg{txO	NHvTcnkyQTl7NkK3Ni=>
H1437	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4P4b542KM7:TR?=	NHnPZ2tFVVOR	MXTJR\|UxRTBwNUKzJO69VQ>?	NYXOOZMyOTl7OU[yO\|I>
BT-20	NXS4fGI3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVi4Zog3hjVizszN	MUXEUXNQ	M2HXVGlEPTB;Mz61OlIh\|ryP	MmDsNVk6QTZ{N{K=
Colo320HSR	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYDPXHZ1hjVizszN	MV;EUXNQ	Ml;UTWM2OD1yLkCxNUDPxE1?	MkfsNVk6QTZ{N{K=
H2087	NFfXdWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3OxU542KM7:TR?=	M2TXOmROW09?	NH;5UZZKSzVyPkGuNFAh\|ryP	NYX5PJQ3OTl7OU[yO\|I>
HCC1419	MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWrTflJHhjVizszN	NET5bHpFVVOR	Mn\STWM2OD1{LkWxO{DPxE1?	Mk\iNVk6QTZ{N{K=
WiDr	NYnHfo5FT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUnVW2hOhjVizszN	M1jyXGROW09?	MnfYTWM2OD1yLkC3OkDPxE1?	MoGyNVk6QTZ{N{K=
H661 0.573	NYezcVRTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVL+OUDPxE1?	Ml;ZSG1UVw>?	NHTwNFBKSzVyPUCuOVc{KM7:TR?=	M{HBbVE6QTl4Mkey
HCC-38	NV[4UmpDT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3y0dp42KM7:TR?=	NHe1V3RFVVOR	Mk[2TWM2OD53LkCwJO69VQ>?	NYLFdG5VOTl7OU[yO\|I>
LS174T	NHniPXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXv+OUDPxE1?	NUDBNWVXTE2VTx?=	M{freGlEPTB;MD61N\|Uh\|ryP	NYC1dWs1OTl7OU[yO\|I>
H211	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEe1VHZ,PSEQvF2=	M3;ofWROW09?	M3LQdmlEPTB;MD63N\|Mh\|ryP	M{DMeFE6QTl4Mkey
HCC70	NYfCNJFTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWT2PWNmhjVizszN	MVfEUXNQ	NIHIfVRKSzVyPUGuOVUh\|ryP	NIi1TIwyQTl7NkK3Ni=>
SW116	Mof2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYfsXHpyhjVizszN	MVjEUXNQ	Mn7kTWM2OD1yLkC2O{DPxE1?	M4\2NlE6QTl4Mkey
H513	M4jjOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MY\+OUDPxE1?	NEDMbHdFVVOR	MUfJR\|UxRTRwNES4JO69VQ>?	NIfadmUyQTl7NkK3Ni=>
MDA-MB-157	NYjqVYpVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX;+OUDPxE1?	NGTTRXpFVVOR	NILCdFNKSzVyPUCuNFM3KM7:TR?=	MYWxPVk6PjJ5Mh?=
H2052	NV;HUFlWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX;+OUDPxE1?	MU\EUXNQ	M2i4bmlEPTB;MT6wOUDPxE1?	NV7hbYlNOTl7OU[yO\|I>
MDA-MB-415	NVvaU5NPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWDucVFChjVizszN	NVvpSGVZTE2VTx?=	NEjI[HVKSzVyPkWuNFAh\|ryP	MmPmNVk6QTZ{N{K=
DLD-1	NFrZN3JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1[1e542KM7:TR?=	M4PufWROW09?	M3vWNmlEPTB;MD65NFkh\|ryP	NYrtRWtxOTl7OU[yO\|I>
H2595	Mnz3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEXVeoJ,PSEQvF2=	NInxOJFFVVOR	MnLJTWM2OD12LkS3OUDPxE1?	NEjkcIkyQTl7NkK3Ni=>
MDA-MB-435S	MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV:2bYRLhjVizszN	NE\zb2hFVVOR	NVq4d4pRUUN3ME2xMlg3QSEQvF2=	NFvpNZQyQTl7NkK3Ni=>
HCT15	NXHISFVVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmH4glUh\|ryP	MVfEUXNQ	MY\JR\|UxRjFwMECg{txO	MmP4NVk6QTZ{N{K=
SK-Hep1	NVm2TmlvT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoOzglUh\|ryP	NW\lOXhWTE2VTx?=	M2XqOGlEPTB;MD6xOFYh\|ryP	MXqxPVk6PjJ5Mh?=
MDA-MB-436	M1foNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVThPXBrhjVizszN	MnziSG1UVw>?	NVjYbZZ{UUN3ME21MlUxOiEQvF2=	Mkn0NVk6QTZ{N{K=
KM12C	MmP6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUPCWYdlhjVizszN	NF[1SoVFVVOR	Ml7QTWM2OD1yLkC1OEDPxE1?	NVuxWoc2OTl7OU[yO\|I>
HEPG2	NXS3fmFFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF:yUVR,PSEQvF2=	MVLEUXNQ	M4LhNmlEPTB;MD6wNlUh\|ryP	Mn20NVk6QTZ{N{K=
MDA-MB-453	NVjB[YtzT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3\lfp42KM7:TR?=	MYrEUXNQ	NFLBcJJKSzVyPUGuPFY6KM7:TR?=	M2niWlE6QTl4Mkey
KM12SM	NYD2T3k1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4C4Wp42KM7:TR?=	M4XsV2ROW09?	M4nPTGlEPTB;MD6wOVkh\|ryP	MVmxPVk6PjJ5Mh?=
1483	MnjzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXv+OUDPxE1?	MVvEUXNQ	MV;JR\|UxRTJwMUmg{txO	NF;aeXoyQTl7NkK3Ni=>
Hs578t	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3zkOp42KM7:TR?=	NVLQU3VLTE2VTx?=	MkfBTWM2OD1zLkK4O{DPxE1?	M3fhd\|E6QTl4Mkey
LS180	Mn;kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFX2NFl,PSEQvF2=	M4DTdWROW09?	M322bmlEPTB;MD62PVYh\|ryP	MV[xPVk6PjJ5Mh?=
FaDu	NVvz[oRTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3\G[J42KM7:TR?=	NF[3VYRFVVOR	MYnJR\|UxRTFwMkeg{txO	M3LJZVE6QTl4Mkey
ZR-75-1	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYn+OUDPxE1?	MoLCSG1UVw>?	M{jSbGlEPTB;Mj6wPFQh\|ryP	M2jVOlE6QTl4Mkey
LS513	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUL1T\|ZbhjVizszN	MlXFSG1UVw>?	MonPTWM2OD1yLkGzOUDPxE1?	M133bFE6QTl4Mkey
Detroit.562	NXnIcHdUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUjlZ3JLhjVizszN	M4D2U2ROW09?	M33UPGlEPTB;MT6xOEDPxE1?	NVK1bGJ3OTl7OU[yO\|I>
ZR-75-30	M4nxO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlzaglUh\|ryP	NV7ZfYl7TE2VTx?=	MUXJR\|UxRjVwMECg{txO	NYDKNIZWOTl7OU[yO\|I>
RKO-PM	MnjoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWjkZXFYhjVizszN	NF;OTpZFVVOR	NX;kXFNRUUN3ME2wMlI{OiEQvF2=	NFLBbokyQTl7NkK3Ni=>
Cal.27	M{fDRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mk\uglUh\|ryP	MUTEUXNQ	Mk\CTWM2OD1{IN88US=>	MVWxPVk6PjJ5Mh?=
KPL4	NIPDbY5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NX60ZVRIhjVizszN	NIrVO4pFVVOR	MWnJR\|UxRTFwMkWyJO69VQ>?	MXuxPVk6PjJ5Mh?=
PKO-RM13	NGDuNm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mk\SglUh\|ryP	M2\qSWROW09?	NUjDOmczUUN3ME2wMlQzPSEQvF2=	MmPuNVk6QTZ{N{K=
HS.53.T	MnnqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVjGWlB[hjVizszN	NYLCSo1[TE2VTx?=	M13WdGlEPTB;MD63PUDPxE1?	MmHNNVk6QTZ{N{K=
EMT6	M{CzUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUHiTXRihjVizszN	M4HENWROW09?	MYjJR\|UxRTBwOEC2JO69VQ>?	NXTj[3dCOTl7OU[yO\|I>
SNU-C1	M2\1[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4fxeJ42KM7:TR?=	MWjEUXNQ	MVXJR\|UxRTBwMEC3JO69VQ>?	MlHONVk6QTZ{N{K=
SQCCY1	Mm\WS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWr+OUDPxE1?	MYXEUXNQ	NUPZbYZHUUN3ME2wMlc6KM7:TR?=	MoPrNVk6QTZ{N{K=
SW480	M3zpb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYXaNZQ6hjVizszN	MX;EUXNQ	MmnHTWM2OD1yLkCzO{DPxE1?	MVixPVk6PjJ5Mh?=
SCC9	NYHTdmZ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVn+OUDPxE1?	NXqwZ45JTE2VTx?=	NUD1bFZ6UUN3ME2wMlc2KM7:TR?=	MYWxPVk6PjJ5Mh?=
SK-LMS-1	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEHWU5d,PSEQvF2=	M4\RXmROW09?	NYG2[oZvUUN3ME2wMlY5PyEQvF2=	NHH2THIyQTl7NkK3Ni=>
SCC25	NUfKXYJzT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnfZglUh\|ryP	M3vlRWROW09?	NFGwdlRKSzVyPUCuOlgh\|ryP	NWDu[mF6OTl7OU[yO\|I>
U87	MnHxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGDkNVR,PSEQvF2=	MlPmSG1UVw>?	NUfwdIJFUUN3ME2wMlk2KM7:TR?=	MUGxPVk6PjJ5Mh?=
SCC15	NVLQeXdFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWP+OUDPxE1?	NFjaUndFVVOR	Mo\DTWM2OD1yLk[3JO69VQ>?	M4\G[lE6QTl4Mkey
T98G	NHrjZVRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3\UUZ42KM7:TR?=	MoLISG1UVw>?	MmTOTWM2OD1zLkKxPEDPxE1?	M1vseFE6QTl4Mkey
SCC4	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkX4glUh\|ryP	MVfEUXNQ	NIr0NGxKSzVyPUCuOlMh\|ryP	MXexPVk6PjJ5Mh?=
U118	NIC4RWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NI[zbHl,PSEQvF2=	MoTnSG1UVw>?	M{jQWmlEPTB;MT62NVgh\|ryP	MVexPVk6PjJ5Mh?=
TU167	M3nDc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWPx[HVShjVizszN	M4Tac2ROW09?	MX7JR\|UxRTRwNUKg{txO	MnLhNVk6QTZ{N{K=
NCI-H727	M1rDNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkXGglEx6oDMzszN	MXHEUXNQ	MW\JR\|UxRTR{ODDuUS=>	NHn2XWkzODN6NUe0Oy=>
NCI-H720	NHjJS4NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlG0glEx6oDMzszN	NGn5U2xFVVOR	MYPJR\|UxRTJwODFOwG0>	MknONlA{QDV5NEe=
NCI-H835	NF7vUmpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1zCfJ4yOOLCit88US=>	NX;qNHY3TE2VTx?=	MXXJR\|UxRTFizszN	MlPmNlA{QDV5NEe=
NCI-H727	NEHKVFFMcW6jc3WgZZN{[Xl?	NWftOo1mhjFy4pEK{txO	NEDXUHdFVVOR	Mo\rbY5pcWKrdIOgZ49ve3SrdIX0bZZmKEmJRkHSJIF2fG:yaH;zdIhwenmuYYTpc44>	M1\HRVIxOzh3N{S3
RD	M3LDXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NED0WZJ,OTEkgJtOwG0>		Ml7xTWM2OD1zLkGyJOK2VQ>?	NWD1RlZxOjF{OUi3OFU>
Rh41	MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3zHcZ4yOOLCit88US=>		NIf5PWRKSzVyPUCuNFchyrWP	NWG4V2ZUOjF{OUi3OFU>
Rh18	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXLqR4tVhjFy4pEK{txO		M1i5O2lEPTB;ND65OkDDvU1?	NFTafZMzOTJ7OEe0OS=>
Rh30	NH3IeYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIXJcFN,OTEkgJtOwG0>		M3jDW2lEPTB;MD6xPUDDvU1?	NYjKcYRpOjF{OUi3OFU>
BT-12	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWnCbmI2hjFy4pEK{txO		MlHKTWM2OD1yLke4JOK2VQ>?	NWXJSopbOjF{OUi3OFU>
CHLA-266	NFTtSXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4TROZ4yOOLCit88US=>		NX7CZmw5UUN3ME2wMlg6KML3TR?=	NIHFTnMzOTJ7OEe0OS=>
TC-71	NYrvc\|A{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmfZglEx6oDMzszN		M3OwO2lEPTB;MD6xNUDDvU1?	NIXIXFQzOTJ7OEe0OS=>
CHLA-9	M1vlRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NU\QUpZDhjFy4pEK{txO		NVizWFlOUUN3ME2wMlEzKML3TR?=	M3nkZ\|IyOjl6N{S1
CHLA-10	MmWxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mlf1glEx6oDMzszN		MW\JR\|UxRTBwNkKgxtVO	M{DlZlIyOjl6N{S1
CHLA-258	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXXpZm1UhjFy4pEK{txO		M3nUNmlEPTB;MD6yO{DDvU1?	Ml;rNlEzQTh5NEW=
GBM2	NULmOGs4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1ntbZ4yOOLCit88US=>		MmC5TWM2OD1zLkS3JOK2VQ>?	NWTSNZNQOjF{OUi3OFU>
NB-1643	MofXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIriVJR,OTEkgJtOwG0>		NYDrOpcxUUN3ME2wMlEzKML3TR?=	MnHVNlEzQTh5NEW=
NB-EBc1	NVuwWnFbT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXK3RZlDhjFy4pEK{txO		NIXHeWxKSzVyPUCuN\|UhyrWP	NF;yNXozOTJ7OEe0OS=>
CHLA-90	NVS4PFVvT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MV;+NVDjiIsQvF2=		M3\iOmlEPTB;MD63O{DDvU1?	MW[yNVI6QDd2NR?=
CHLA-136	NUSzRY82T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MW\+NVDjiIsQvF2=		MVPJR\|UxRTBwNUKgxtVO	MYWyNVI6QDd2NR?=
NALM-6	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYT+NVDjiIsQvF2=		NXfM[5JMUUN3ME2wMlQ6KML3TR?=	NWf1flVOOjF{OUi3OFU>
COG-LL-317	NFnnTItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MV3+NVDjiIsQvF2=		NYP2V245UUN3ME2xMlM5KML3TR?=	MkLYNlEzQTh5NEW=
RS4;11	MnnJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXX+NVDjiIsQvF2=		MVLJR\|UxRTBwM{igxtVO	NFjoOXozOTJ7OEe0OS=>
MOLT-4	NYTrZ45{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFvle3B,OTEkgJtOwG0>		M3e2eGlEPTB;MD61N{DDvU1?	NXrvNFJoOjF{OUi3OFU>
CCRF-CEM	M3ridWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnqwglEx6oDMzszN		NGfHPYJKSzVyPUGuNVMhyrWP	MWGyNVI6QDd2NR?=
Kasumi-1	NX;kXlZrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1zB[p4yOOLCit88US=>		NGP4UnBKSzVyPUGuNkDDvU1?	MUeyNVI6QDd2NR?=
Karpas-299	M1zZS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFvib4l,OTEkgJtOwG0>		NYn3ZYNuUUN3ME2xMlY1KML3TR?=	NX:zOItrOjF{OUi3OFU>
Ramos-RA1	M4HzTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUm4b2M6hjFy4pEK{txO		MW\JR\|UxRTFwM{GgxtVO	NWCzRY9TOjF{OUi3OFU>
Rh30	NYLWenB5TnWwY4Tpc44h[XO\|YYm=			NF7IfW1qdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	NFuwW2czPTl{NUO3PC=>
Rh41	MmW1SpVv[3Srb36gZZN{[Xl?			NIHPUnRqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	MUKyOVkzPTN5OB?=
RD	NI\jTnNHfW6ldHnvckBie3OjeR?=			M4T2[Ylv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	NG[4UIkzPTl{NUO3PC=>
A549	NGOwWW5McW6jc3WgZZN{[Xl?	MXOwMlXjiIsQvF2=	NUL3RYoyTE2VTx?=	NVjBPGNpcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?	MnPVNlY6Ojh3N{i=
NCI-H358	M4\DVmtqdmG\|ZTDhd5NigQ>?	NWXjVWJKOC534pEK{txO	MYjEUXNQ	MoHRbY5pcWKrdIOgTWdHNUmUL1nSJIFkfGm4YYTpc44>	NUnFUVlNOjZ7Mki1O\|g>
A549	MXzGeY5kfGmxbjDhd5NigQ>?	MWOwMlXjiIsQvF2=	Mo\ZSG1UVw>?	M1XMOYNifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt?	NW[1b2VwOjZ7Mki1O\|g>
NCI-H358	M2LtU2Z2dmO2aX;uJIF{e2G7	NGHtS4gxNjYkgJtOwG0>	NWLGcYN[TE2VTx?=	MY\jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	Mnv1NlY6Ojh3N{i=
A549	Ml[3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWX+NVDjiIsQvF2=	NGnNXpVFVVOR	NF7FVVFKSzVyPUCuO\|Yh\|ryP	MYOyOlkzQDV5OB?=
NCI-H358	NXTFbZdpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWD+NVDjiIsQvF2=	NYPZVmtJTE2VTx?=	MWHJR\|UxRTFwMEmg{txO	Mn23NlY6Ojh3N{i=
A549	MonzRZBweHSxc3nzJIF{e2G7	M{LPPVAvPeLCit88US=>	M4jvdGROW09?	NILMOpBqdmS3Y3XzJGFxd3C2b4Ppdy=>	NYXpToh1OjZ7Mki1O\|g>
NCI-H358	M1;kVGFxd3C2b4Ppd{Bie3OjeR?=	NFLUSWYxNjYkgJtOwG0>	Ml30SG1UVw>?	NXvLN3dYcW6mdXPld{BCeG:ydH;zbZM>	NHW2TmQzPjl{OEW3PC=>
A549	M1HNVGZ2dmO2aX;uJIF{e2G7	MViwMlXjiIsQvF2=	MWfEUXNQ	NWXMT5k4emWmdXPld{B4d3WwZDDjcI9{fXKn	NILmdmwzPjl{OEW3PC=>
NCI-H358	M3\wcmZ2dmO2aX;uJIF{e2G7	NFLKNmkxNjYkgJtOwG0>	MVjEUXNQ	MlfJdoVlfWOnczD3c5Vv\CClbH;zeZJm	NGC1OYwzPjl{OEW3PC=>

... Click to View More Cell Line Experimental Data

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	+ Expand Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	+ Expand Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products4

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324|Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 7 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 7 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)